J&J: will present data in lung cancer
Key data to be presented in four oral mini-presentations include the results of an analysis of a Phase 3 study evaluating the effect of dose interruptions of Rybrevant, as well as new data on the monthly subcutaneous administration of amivantamab (Phase 1b) and analyses to support the differentiated clinical profile of Rybrevant in the treatment of patients with EGFR-mutated non-small cell lung cancer.
' The breadth of data presented at ELCC underscores our commitment to redefining treatment outcomes for patients living with EGFR-mutated NSCLC ', said Kiran Patel, M.D., Vice President of Clinical Development, Solid Tumors, Johnson & Johnson Innovative Medicine.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction